The molecular diagnostics company reported total revenues of $56.7 million in the quarter, and saw its testing volume grow 15 percent over Q3 2016.
Carrier screens for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy detected carrier status in one in 20 individuals and led to diagnoses in seven pregnancies.
Core Diagnostics will exclusively offer GenePeeks' preconception screen and advanced analytics platform in 29 states and seven territories in India.
The new deal, which covers Greece and Cyrus, follows a series of partnerships with fertility organizations and a separate distribution pact signed earlier this year.
The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.
Natera has entered the oncology space with a ctDNA assay and sees its blood banking service as a way to eventually tap into the consumer genomics space.
Natera ran 17 percent more tests in Q2 than it did in the prior-year period, generating $53.6 million in total revenues.
Quest's QHerit will screen for 22 disorders and is based on recommendations issued this year by the American College of Obstetricians and Gynecologists.
Under an agreement, Angsana's network of physicians in Hong Kong will be able to order Counsyl's expanded carrier screening test.
Over the next month the company plans to expand its preconception screening test, which it launched widely earlier this year, by adding about 90 X-linked disorders.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.